Pipeline & Science

Pipeline of 6 novel assets in late-stage clinical development targeting 8 indications

Assets*

Indications

Pre-Clinical

Phase 1

Phase 2

Phase 3

Approval

Cardiovascular

Omecamtiv Mecarbil
(cardiac myosin activator)

HFrEF

China participated the global multi-center Ph3 study, preparing NDA filing
FDA accepted NDA with PDUFA target action date Nov 30th 2022

oHCM

Ph1 completed | Joining global Ph3 in Q2 2022
Ph2 REDWOOD-HCM (dataset released) | To start global Ph3 in Q1 2022

Aficamten
formerly CK274
(cardiac myosin inhibitor)

nHCM

To be initiated
Ph2 to be initiated in 2022

HFpEF

To be initiated
Ph2 to be initiated in 2022

Etripamil Nasal Spray

PSVT

Initiate Ph3 and parallel PK studies in 2H 2022
Ph3 completion in Q3 2022

(short-acting calcium channel blocker)

Atrial fibrillation (AFib)

To be initiated
Ph2 initiated in Q2 2021

Ophthalmology

OC-01 Nasal Spray
(nAChR agonist in preservative-free formulation)

Dry eye disease

Initiate Ph3 and parallel Ph1 study in 2H 2022
FDA Approval received October 2021

OC-02 Nasal Spray
(nAChR agonist)

Dry eye disease

Initiate Ph3 and parallel Ph1 study in 1H 2024
Ph2b studies completed

LNZ100/101
(parasympathomimetic miotic agent)

Presbyopia

Joining global Ph3 in 2023 or initiate standalone Ph3 in 2023
Ph2b studies completed; initiating Ph3

JX08
(a preclinical ophthalmology program)

Preclinical program
Preclinical program

* Ji Xing has exclusive Greater China rights

China studies conducted by Ji Xing
Global studies conducted by partner

1. US Brand name TYRVAYA Source: Clinicaltrials.gov; Cytokinetics; Milestone Pharmaceuticals; Oyster Point Pharma;
Note: oHCM = obstructive hypertrophic cardiomyopathy, nHCM = non-obstructive hypertrophic cardiomyopathy, HFpEF = heart failure with preserved ejection fraction, HFrEF= heart failure with reduced ejection fraction,
PSVT = paroxysmal supraventricular tachycardia.

Pipeline of 4 novel assets in late-stage clinical development targeting 6 indications

* Ji Xing has exclusive Greater China rights

China studies conducted by Ji Xing
Global studies conducted by partner

Source: Clinicaltrials.gov; Cytokinetics; Milestone Pharmaceuticals; Oyster Point Pharma;
Note: oHCM = obstructive hypertrophic cardiomyopathy, nHCM = non-obstructive hypertrophic cardiomyopathy, HFpEF = heart failure with preserved ejection fraction, PSVT = paroxysmal supraventricular tachycardia.

Scroll to Top